Inhibikase Therapeutics (IKT) Cash from Operations Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | -193.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -193.89% |
| Dec 31, 2025 | -40.60% |
| Sep 30, 2025 | -117.02% |
| Jun 30, 2025 | -10.29% |
| Mar 31, 2025 | -6.12% |
| Dec 31, 2024 | -55.28% |
| Sep 30, 2024 | -18.90% |
| Jun 30, 2024 | -10.71% |
| Mar 31, 2024 | 35.25% |
| Dec 31, 2023 | 3.20% |
| Sep 30, 2023 | 25.43% |
| Jun 30, 2023 | -4.81% |
| Mar 31, 2023 | -51.80% |
| Dec 31, 2022 | 13.17% |
| Sep 30, 2022 | -172.44% |
| Jun 30, 2022 | -2.57% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | -332.72% |
| Sep 30, 2021 | -2,775.62% |
| Jun 30, 2021 | -145,828.38% |